1.
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
by Ettehad, Dena, MSc
The Lancet (British edition), 2015, Vol.387 (10022), p.957-967
2.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
3.
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
by Jun, Min, MSc
The Lancet (British edition), 2010, Vol.375 (9729), p.1875-1884
4.
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
by Chow, Clara K, Prof
The Lancet (British edition), 2017, Vol.389 (10073), p.1035-1042
5.
Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
by Welsh, Paul
Diabetologia, 2018-05-04, Vol.61 (7), p.1581-1591
6.
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes
by Zoungas, Sophia
Diabetologia, 2014-09-17, Vol.57 (12), p.2465-2474
7.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
by Fox, Caroline S, MD
The Lancet (British edition), 2012, Vol.380 (9854), p.1662-1673
8.
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
by Oshima, Megumi
Diabetologia, 2019-07-13, Vol.62 (11), p.1988-1997
9.
10.
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
by van der Leeuw, Joep
Diabetologia, 2016-12, Vol.59 (12), p.2603–2612-2612
11.
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus results from action in diabetes and...
by Van Der Leeuw, Joep
Hypertension (Dallas, Tex. 1979), 2015-01-01, Vol.65 (1), p.115-121
12.
The ADVANCE trial – Authors' reply
by Patel, Anushka
The Lancet (British edition), 2008, Vol.371 (9606), p.26-26
13.
How to increase value and reduce waste when research priorities are set
by Chalmers, Iain, DSc
The Lancet (British edition), 2014, Vol.383 (9912), p.156-165
14.
Biomedical research: increasing value, reducing waste
by Macleod, Malcolm R
The Lancet (British edition), 2014, Vol.383 (9912), p.101-104
15.
Challenges in evaluating surgical innovation
by Ergina, Patrick L, Dr
The Lancet (British edition), 2009, Vol.374 (9695), p.1097-1104
16.
Evaluation and stages of surgical innovations
by Barkun, Jeffrey S, Prof
The Lancet (British edition), 2009, Vol.374 (9695), p.1089-1096
17.
No surgical innovation without evaluation: the IDEAL recommendations
by McCulloch, Peter, MD
The Lancet (British edition), 2009, Vol.374 (9695), p.1105-1112
18.
Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial
by Geddes, John R
The Lancet (British edition), 2010, Vol.375 (9712), p.385-395
19.
Research: increasing value, reducing waste – Authors' reply
by Glasziou, Paul
The Lancet (British edition), 2014, Vol.383 (9923), p.1126-1127
20.
Progress of The Lancet Palestinian Health Alliance
by Watt, Graham
The Lancet (British edition), 2014, Vol.383 (9914), p.e5-e6
Filter electronic articles 22 Hits
Remove Filters
- Subjects
- Internal Medicine
- Humans (18)
- Science & Technology (17)
- more ...